603882 Guangzhou Kingmed Diagnostics Group
- 37.54
- -1.54-3.94%
Guangzhou Kingmed Diagnostics Group News
Jinyu Medical (603882): Short-term results are under pressure and profitability is expected to pick up
Maintain an increase in holdings rating. Taking into account the pace of recovery of routine medical examination services and preparation for credit impairment of accounts receivable, the 2024-2025 EPS forecast was lowered to 1.49/2.04 yuan (previously 2.14/3.17 yuan), forecast
Jinyu Medical (603882.SH): A total of 705,000 shares have been repurchased
Gelonghui, May 6, 丨 Jinyu Medical (603882.SH) announced that as of April 30, 2024, the company had repurchased 705,000 shares, accounting for 0.1504% of the company's total share capital. The highest purchase price was 46.97 yuan/share, the lowest price was 38.05 yuan/share, and the total amount paid was 29,037,887.86 yuan (not including transaction fees).
The Three-year Shareholder Returns and Company Earnings Persist Lower as Guangzhou Kingmed Diagnostics Group (SHSE:603882) Stock Falls a Further 9.0% in Past Week
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of Guangzhou Kingmed Diagnost
Jinyu Medical (603882): Affected by the external environment and credit impairment, short-term pressure waits for an upward inflection point in profits
Core view: Jinyu Medical announced the 2023 and 2024Q1 results. In '23, the company achieved revenue of 8.540 billion yuan (-44.82%); net profit to mother of 643 million yuan (-76.64%); after deducting non-payment
Jinyu Medical (603882): High base fluctuation routine has resumed
Key investment performance: 2023: revenue of 8.54 billion yuan, YOY -44.8%; net profit to mother of 640 million yuan, YOY -76.6%; net profit after deducting non-return to mother of 360 million yuan, YOY -8
Jinyu Medical (603882) 2023 Annual Report and 2024 Quarterly Report Review: Business Structure Optimization and Rapid Improvement of Testing Programs
Incident: The company announced its 2023 annual report. In 2023, it achieved operating income of 8.540 billion yuan, a year-on-year decrease of 44.82%; realized net profit to mother of 643 million yuan, a year-on-year decrease of 76.64%. The company announced at the same time
Jinyu Medical (603882): Routine medical diagnostic services increased 15%, profitability is expected to recover
Incident: The company released its annual report for the year 20223 and the quarterly report for 2024. In 2023, it achieved operating income of 8.540 billion yuan (yoy -44.82%) and net profit to mother of 643 million yuan (yoy-76.64)
Jinyu Medical (603882): 2023 results are in line with expectations, regular business growth is steady
The 2023 results are in line with market expectations, and the 1Q24 results are lower than market expectations. The company announced 2023 results: revenue of 8.540 billion yuan, down 44.8% year on year, and net profit to mother of 643 million yuan, down 7 percent year on year
A-share changes | Jinyu Medical fell more than 9% to hit a new low Q1 net profit and loss year-on-year
GLONGHUI, April 26 | Jinyu Medical (603882.SH) fell sharply by more than 9%. The low was 37.95 yuan, the decline since September 2019, and the total market value fell below 18 billion yuan. On the message. The company achieved operating income of 1,841 billion yuan in the first quarter, a year-on-year decrease of 13.05%, and realized net profit attributable to mother of -0.19 million yuan, from profit to loss over the previous year, and realized net cash flow from operating activities of -138 million yuan, which turned negative year-on-year. The company's net revenue and profit both declined in 2023, and the results of the first quarter of this year continued to be under pressure.
Jinyu Medical (603882.SH) announced its 2023 annual results. Net profit of 643 million yuan decreased by 76.64% year on year
Jinyu Medical (603882.SH) released the 2023 annual performance report. The company achieved operating income of 8 during the reporting period...
Express News | Jinyu Medical: Cooperate with Kangrun Biotech to develop an intelligent immunofluorescence detection platform
Jinyu Medical (603882.SH): Initial repurchase of 45,000 shares
Gelonghui, April 16, 丨 Jinyu Medical (603882.SH) announced that on April 16, 2024, the company implemented the first repurchase of the company's shares through the Shanghai Stock Exchange trading system. The company repurchased a total of 45,000 shares for the first time through centralized bidding transactions, accounting for 0.0096% of the company's current total share capital. The highest price of the repurchase transaction was 46.97 yuan/share, and the lowest price was 46.24 yuan/share. The total amount paid was RMB 2,09728.00 (excluding transaction fees and other fees).
Jinyu Medical: Chairman proposes to buy back the company's shares for 50 million yuan
Jinyu Medical announced that the chairman proposed to repurchase the company's shares for 50 million yuan.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882)?
Guangzhou Kingmed Diagnostics Group (SHSE:603882) has had a rough month with its share price down 6.7%. However, stock prices are usually driven by a company's financial performance over the long te
Jinyu Medical (603882.SH) has spent 84.748,900 yuan to buy back 1.496 million shares
Jinyu Medical (603882.SH) issued an announcement. As of March 31, 2024, the repurchase plan company...
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Guolian Securities: Medical AI empowers the healthcare industry chain and focuses on companies with leading technology layout and strong commercialization capabilities
Healthcare is one of the important fields of large-scale application of artificial intelligence technology (AI).
Express News | Cinda Securities: Focus on investment opportunities brought about by medical equipment updates
Recent Uptick Might Appease Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) Institutional Owners After Losing 20% Over the Past Year
Key Insights Institutions' substantial holdings in Guangzhou Kingmed Diagnostics Group implies that they have significant influence over the company's share price The top 7 shareholders own 51% of t
Jinyu Medical (603882.SH): It has repurchased a total of 1.092,600 shares at a cost of 61.44,900 yuan
Gelonghui, March 1, 丨 Jinyu Medical (603882.SH) announced that as of February 29, 2024, the company had repurchased a total of 1.0926 million shares, accounting for 0.2331% of the company's total share capital. The highest purchase price was 60.67 yuan/share, the lowest price was 51.17 yuan/share, and the total amount paid was 61.44,900 yuan (not including transaction fees, etc.).
Analysis
Price Target
No Data
